Comparative Pharmacology
Head-to-head clinical analysis: THIORIDAZINE HYDROCHLORIDE INTENSOL versus THIOTHIXENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THIORIDAZINE HYDROCHLORIDE INTENSOL versus THIOTHIXENE.
THIORIDAZINE HYDROCHLORIDE INTENSOL vs THIOTHIXENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a typical antipsychotic of the phenothiazine class. It blocks dopamine D2 receptors in the brain, particularly in the mesolimbic pathway, and also exhibits antagonism at alpha-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the brain. It also has alpha-adrenergic and histamine H1 blocking activity, with minimal anticholinergic effects.
50 mg orally twice daily initially, titrated to 200-800 mg/day in divided doses. Maximum 800 mg/day.
Initial: 2 mg orally three times daily; maintenance: 5-30 mg/day orally in divided doses; maximum: 60 mg/day. IM: 4 mg 2-4 times daily; maximum 30 mg/day.
None Documented
None Documented
Clinical Note
moderateThiothixene + Deferasirox
"The serum concentration of Deferasirox can be increased when it is combined with Thiothixene."
Clinical Note
moderateThiothixene + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluticasone propionate."
Clinical Note
moderateThiothixene + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Thiothixene."
Clinical Note
moderateTerminal elimination half-life ranges from 21 to 30 hours (mean 24 h). In elderly or patients with hepatic impairment, half-life may be prolonged. Requires multiple days to reach steady state.
Terminal half-life: 10-20 hours (mean ~14 h). Clinical context: Steady-state achieved in ~2-3 days; allows once-daily dosing for maintenance.
Primarily hepatic metabolism with <1% excreted unchanged in urine; metabolites eliminated in bile and feces. Approx. 30–40% of a dose appears in urine as metabolites (mostly sulfoxides and side-chain oxidized products) and 50–60% in feces.
Primarily renal: 65-70% as metabolites, <1% unchanged. Fecal: 15-20% via biliary elimination.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
Thiothixene + Methylphenidate
"The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate."